Thermo Fisher Scientific Stock-based compensation expense decreased by 12.0% to $44.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.0%, from $50.00M to $44.00M. This increase may warrant attention — for this metric, lower values are generally preferred.
Rising expenses may indicate increased reliance on equity incentives or higher valuation of awards, impacting reported operating margins.
This metric measures the total expense recognized in the income statement for share-based payment awards granted to empl...
Standard operating expense item for public companies with equity incentive programs.
cat_stock_based_compensation_expense| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $87.00M | $29.00M | $2.00M | $95.00M | $5.00M | $34.00M | $65.00M | $32.00M | $103.00M | $81.00M | $75.00M | $50.00M | $44.00M |
| QoQ Change | — | -66.7% | -93.1% | >999% | -94.7% | +580.0% | +91.2% | -50.8% | +221.9% | -21.4% | -7.4% | -33.3% | -12.0% |
| YoY Change | — | — | — | +9.2% | -82.8% | >999% | -31.6% | +540.0% | +202.9% | +24.6% | +134.4% | -51.5% | -12.0% |